Adial Pharmaceuticals Inc.

ADIL | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.40

-$0.46 (-9.47%)

At close: Sep 21, 2026, 4:00 PM ET

$4.48

+$0.08 (+1.82%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $4.66M

Enterprise Value $-24.49M

Beta 1.39

Average Volume 341.26K

Shares Outstanding (Diluted) 4.62M

Shares Change YoY 987.7%

Institutional Ownership 2.60%

Exchange NASDAQ

ISIN US00688A3041

Price Performance

Price Change 1M -19.9%

Price Change 3M 72.5%

Price Change 6M 154.3%

Price Change YTD -26.7%

Price Change 1Y -48.2%

Price Change 3Y -93.0%

Price Change 5Y -99.8%

1M CAGR (ann.) 1.3%

1Y CAGR (ann.) -44.5%

5Y CAGR (ann.) -71.5%

All-Time CAGR -53.6%

Valuation

PE Ratio -0.27

Forward PE N/A

PEG Ratio 0.01

Forward PEG 0.00

PS Ratio N/A

Forward PS 1.00

PB Ratio 27.07

P/FCF Ratio -0.38

P/Adj. FCF Ratio -0.36

P/OCF Ratio -1.83

EV/Sales N/A

EV/EBIT 0.42

EV/EBITDA 0.42

EV/FCF 2.20

Earnings Yield -375.7%

FCF Yield -263.7%

Adj. FCF Yield -277.9%

Financial Health

Net Cash $28.71M

Total Debt $0

Cash & Short-Term Investments $28.71M

Total Assets $29.09M

Current Ratio 5.63

Quick Ratio 5.63

Debt / Equity Ratio 0.00

Debt / EBITDA -0.00

Debt / FCF -0.00

OCF / Debt N/A

Interest Coverage 0.00

Altman Z-Score -12.41

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -5.4%

Returns

Return on Assets -198.7%

Return on Equity -1693.2%

Return on Invested Capital -240.6%

Return on Capital Employed -240.6%

Return on Tangible Assets -198.7%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 98.4%

EPS CAGR 5Y 65.3%

EPS CAGR 10Y 15.9%

FCF CAGR 3Y -39.3%

FCF CAGR 5Y 3.0%

FCF CAGR 10Y -13.3%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 3

EPS Growth Next 3Y 29.5%

Revenue Growth Next 3Y N/A

Earnings Date Nov 17, 2026

EPS Estimate (next Q) -$0.17

EPS Growth Est (next Q) -91.3%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $8.50

Price Target Upside 93.2%

Cash Flow

Operating Cash Flow $-11.13M

Free Cash Flow $-11.13M

Adj. Free Cash Flow $-11.73M

FCF Per Share -$2.41

OCF Per Share -$2.41

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $0

Operating Income $-57.68M

EBITDA $-57.8M

Net Income $-57.8M

EPS (Diluted) -$16.53

Revenue / Employee N/A

Profit / Employee $-11.56M

Employees 5